Other Events ·
On August 31, 2026, Ascendis Pharma entered a binding term sheet for a global settlement and license agreement with…
ASNDAscendis Pharma A/S
On August 31, 2026, Ascendis Pharma entered a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical to resolve all litigation. BioMarin granted Ascendis a non-exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialize navepegritide-related products without restriction, while waiving certain regulatory rights and dismissing proceedings. In exchange, Ascendis agreed to dismiss its claims against BioMarin and pay royalties equal to 20% of net sales in the United States and 18% in the European Union, South Korea, and Brazil from the first commercial sale through May 20, 30. This agreement secures Ascendis' freedom to operate for its navepegritide pipeline. The company operates in the biotechnology industry, focusing on developing therapies for rare diseases.